Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Ascelia Pharma AB

Market Cap 38Cr 4Cr 3.45Cr 3.17Cr 2.97Cr 5.59Cr 380.61Cr 5.65Cr 15Cr 185.27Cr 15Cr 15Cr 644.95Cr P/E Ratio 2026 *
14.3x
P/E Ratio 2027 * 28.1x
Enterprise Value 28Cr 2.99Cr 2.57Cr 2.37Cr 2.22Cr 4.17Cr 284.25Cr 4.22Cr 11Cr 138.36Cr 11Cr 11Cr 481.67Cr EV / Sales 2026 *
3.23x
EV / Sales 2027 * 3.99x
Free-Float
87.88%
Yield 2026 *
-
Yield 2027 * -
1 day+0.90%
1 week-3.10%
Current month-9.06%
1 month-4.10%
3 months-6.33%
6 months-5.55%
Current year-12.60%
1 week 2.76
Extreme 2.755
2.92
1 month 2.76
Extreme 2.755
3.55
Current year 2.58
Extreme 2.575
3.55
1 year 2.53
Extreme 2.53
5.23
3 years 2
Extreme 2
17.98
5 years 2
Extreme 2
39.85
10 years 2
Extreme 2
66.7
Manager TitleAgeSince
Chief Executive Officer 51 01/01/2014
Director of Finance/CFO 35 -
Chief Operating Officer 42 01/11/2025
Director TitleAgeSince
Chairman 71 01/06/2017
Director/Board Member 61 01/01/2017
Director/Board Member 71 01/01/2017
Date Insider Type Main position Quantity % Market Cap.
23/25/23Buy

Chairman

15,000 0.0156%
23/25/23Buy

Chairman

8,000 0.0083%
03/24/03Sell

Chief Executive Officer

1,12,645 0.3337%
Change 5-day change 1-year change 3-year change Capi.($)
+0.90%-3.10%-36.35%-82.57% 3.99Cr
-0.35%+0.97%-13.80%-13.25% 4.3TCr
+3.11%+3.11%+279.08%+501.52% 3.27TCr
+0.22%-1.08%+15.66%-15.65% 3.03TCr
+1.62%-2.08%-1.91%+24.64% 2.94TCr
+4.09%+0.93%+12.97%+20.22% 2.51TCr
+1.14%+3.62% - - 1.35TCr
-1.63%+2.88%+56.69%+113.41% 1.33TCr
-0.40%-1.29%+6.23%+7.63% 1.3TCr
-0.74%-1.62%+105.89%+74.92% 1.21TCr
Average +0.80%+0.99%+47.16%+70.10% 2.13TCr
Weighted average by Cap. +1.05%+1.48%+57.28%+96.04%

Financials

2026 *2027 *
Net sales 8.67Cr 92.47L 79.66L 73.35L 68.74L 1.29Cr 88Cr 1.31Cr 3.38Cr 43Cr 3.47Cr 3.4Cr 149.06Cr 6.66Cr 71.01L 61.17L 56.33L 52.79L 99.13L 68Cr 1Cr 2.59Cr 33Cr 2.67Cr 2.61Cr 114.47Cr
Net income 2.38Cr 25.43L 21.91L 20.17L 18.9L 35.5L 24Cr 35.93L 92.93L 12Cr 95.45L 93.43L 41Cr 1.68Cr 17.94L 15.45L 14.23L 13.34L 25.04L 17Cr 25.35L 65.56L 8.31Cr 67.34L 65.91L 29Cr
Net Debt -9.5Cr -1.01Cr -87.26L -80.35L -75.3L -1.41Cr -96Cr -1.43Cr -3.7Cr -47Cr -3.8Cr -3.72Cr -163.29Cr -11Cr -1.17Cr -1.01Cr -92.75L -86.92L -1.63Cr -111.24Cr -1.65Cr -4.27Cr -54Cr -4.39Cr -4.3Cr -188.5Cr
Logo Ascelia Pharma AB
Ascelia Pharma AB is a Sweden-based pharmaceutical company focused on the development of novel oncology therapies. The Company identifies, acquires and develops differentiated, underappreciated and derisked investigational medicinal drug candidates to make them available to cancer patients. The Company's pipeline includes Mangoral and Oncoral. Mangoral is a medical imaging drug candidate for use in liver Magnetic Resonance Imaging (MRI) for detection and localization of liver metastases in patients with impaired kidneys, which has completed phase II of clinical studies. Oncoral is a tablet formulation of chemotherapeutic agent irinotecan under clinical development for the treatment of gastric cancer. It has completed phase I of clinical studies.
Employees
10
Date Price Change Volume
12/26/12 2.810 kr +0.90% 4,91,158
11/26/11 2.785 kr -3.63% 7,24,986
10/26/10 2.890 kr +0.87% 5,09,720
09/26/09 2.865 kr -0.69% 7,20,332
08/26/08 2.885 kr -0.52% 6,06,809
Trader
Investor
Global
-
Quality
-
ESG MSCI
-

Quarterly revenue - Rate of surprise

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!